How has been the historical performance of Windlas Biotech?

Answer:The historical performance of Windlas Biotech shows a consistent growth trajectory in net sales and profitability over the past several years.

Breakdown:
Windlas Biotech's net sales have steadily increased from INR 328.85 crore in March 2020 to INR 759.88 crore in March 2025. This growth is reflected in total operating income, which rose from INR 328.85 crore to INR 759.88 crore during the same period. The company's total expenditure, excluding depreciation, also grew, reaching INR 665.77 crore in March 2025, up from INR 287.39 crore in March 2020. Operating profit (PBDIT) has shown a positive trend, climbing from INR 43.95 crore in March 2020 to INR 112.13 crore in March 2025, while profit before tax increased from INR 32.14 crore to INR 79.76 crore. Profit after tax followed suit, rising from INR 16.21 crore in March 2020 to INR 60.99 crore in March 2025. The company's total assets grew significantly from INR 337.82 crore in March 2020 to INR 760.17 crore in March 2025, while total liabilities increased from INR 296.12 crore to INR 760.17 crore. Cash flow from operating activities improved from INR 25 crore in March 2020 to INR 68 crore in March 2025, although cash flow from investing activities remained negative throughout this period. Overall, Windlas Biotech has demonstrated robust growth in key financial metrics over the years.